Company
Compugen Ltd
NASDAQ:CGEN
Compugen Ltd is a clinical-stage drug discovery and development company utilizing a broadly applicable, predictive computational discovery platforms to identify novel drug targets and new biological pathways and develop therapeutics in the field of cancer immunotherapy. Recognizing the potential of immuno-oncology to shift the cancer treatment landscape, the company chose to focus on the discovery of new drug targets to extend the reach of cancer immunotherapies to new patient populations.
5 stories
Bristol-Myers Squibb makes $12 million investment in Compugen, sets up research partnership
New trials will evaluate the safety and tolerability of Compugen’s COM701 in combination with Bristol-Myers' immune checkpoint inhibitor Opdivo in patients with advanced cancerous tumors
EARLY MOVERS: Square shares fall and Compugen shares surge on Bristol-Myers Squibb investment as stock markets in turmoil
Also in focus before the New York bell is taxi app titan Uber and Hurricane Michael
Oppenheimer repeats 'outperform' on Compugen as the Israeli biotech has two candidates cleared for clinic
Broker Oppenheimer repeated an outperform rating on the stock and a punchy target price of US$9
Shares of Compugen gain on US$200mln licensing deal for cancer treatments
Isreali drugmaker will get a US$10mln upfront payment from MedImmune in the deal